Get the Stockscreener App
1.69
4.32%
0.07
Cognition Therapeutics Inc stock is traded at $1.69, with a volume of 1.03M.
It is up +4.32% in the last 24 hours and down -1.74% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.62
Open:
$1.63
24h Volume:
1.03M
Relative Volume:
0.57
Market Cap:
$149.18M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-2.1392
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
-2.31%
1M Performance:
-1.74%
6M Performance:
+448.70%
1Y Performance:
+232.28%
1-Day Range:
$1.61
$1.76
1-Week Range:
$1.61
$1.77
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.69 | 143.00M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why retail investors pile into Cognition Therapeutics Inc. stock2025 Growth vs Value & Daily Momentum Trading Reports - Newser
HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
CGTX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus
Why Cognition Therapeutics Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - Newser
Cognition Therapeutics completes enrollment in expanded access program By Investing.com - Investing.com Nigeria
Cognition Therapeutics completes enrollment in expanded access program - Investing.com India
Cognition Therapeutics Says Zervimesine Expanded Access Program Reaches Full Enrollment - marketscreener.com
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Yahoo Finance
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug By Investing.com - Investing.com Nigeria
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug - Investing.com
Cognition Therapeutics outlines phase 3 Alzheimer's plan at CTAD - marketscreener.com
Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD - TradingView
Cognition Therapeutics, Inc. Plans to Align with EMA on Alzheimer's Disease Strategy for Zervimesine at February 2026 Meeting - Quiver Quantitative
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - Stock Titan
Cognition Therapeutics Inc Stock Analysis and ForecastConsumer Goods Stocks & Affordable Market Investment - earlytimes.in
Cognition Therapeutics Inc. (CGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Recap Report & Free Real-Time Volume Trigger Notifications - BỘ NỘI VỤ
Q1 Earnings Forecast for CGTX Issued By B. Riley - MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics: A High-Stakes Bet On A Single DrugWhy I Hold (NASDAQ:CGTX) - Seeking Alpha
B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
Cognition Therapeutics (CGTX) Sees Analyst Price Target Boost | CGTX Stock News - GuruFocus
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating - marketscreener.com
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - The Manila Times
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Speak at Annual Piper Sandler Healthcare Conference - Quiver Quantitative
Cognition Therapeutics (Nasdaq: CGTX) CEO Talk at 37th Piper Sandler Healthcare Conf - Stock Titan
Will Cognition Therapeutics Inc. stock beat EPS estimatesJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Can Cognition Therapeutics Inc. stock beat analyst upgradesEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
What analyst consensus says on Cognition Therapeutics Inc. stock - newser.com
Will Cognition Therapeutics Inc. stock pay special dividendsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
CGTX: HC Wainwright Reiterates Buy Rating and Price Target | CGT - GuruFocus
How to use a screener to detect Cognition Therapeutics Inc. breakoutsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Cognition Therapeutics Inc. stock appeals to dividend seekersIndex Update & Long-Term Growth Plans - newser.com
Analyzing Cognition Therapeutics Inc. with multi timeframe charts2025 Biggest Moves & Fast Moving Market Watchlists - newser.com
James M. O’Brien Appointed Chief Financial Officer at Mesoblast - GlobeNewswire Inc.
Cognition Therapeutics Announces $30.1M Direct Offering - MSN
Relative strength of Cognition Therapeutics Inc. in sector analysis2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Will earnings trigger a reversal in Cognition Therapeutics Inc.July 2025 Technicals & Real-Time Volume Triggers - newser.com
Will Cognition Therapeutics Inc. stock benefit from upcoming earnings reports2025 Historical Comparison & Reliable Price Breakout Signals - newser.com
Smart tools for monitoring Cognition Therapeutics Inc.’s price actionTrade Ideas & Risk Controlled Swing Trade Alerts - newser.com
Is Cognition Therapeutics Inc. stock cheap at current valuationJuly 2025 Technicals & AI Driven Price Forecasts - newser.com
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):